Fenfluramine
| |
| |
| Fenfluramine
| |
| Systematic (IUPAC) name | |
| N-ethyl-1-[3-(trifluoromethyl)- phenyl]propan-2-amine | |
| Identifiers | |
| CAS number | |
| ATC code | A08 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C12H16F3N |
| Mol. mass | 231.257 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic |
| Half life | 20 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? (United States) |
| Legal status |
Schedule IV, Withdrawn from market |
| Routes | Oral |
|
WikiDoc Resources for Fenfluramine | |
|
Articles | |
|---|---|
|
Most recent articles on Fenfluramine Most cited articles on Fenfluramine | |
|
Media | |
|
Powerpoint slides on Fenfluramine | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Fenfluramine at Clinical Trials.gov Clinical Trials on Fenfluramine at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Fenfluramine
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Fenfluramine Discussion groups on Fenfluramine Patient Handouts on Fenfluramine Directions to Hospitals Treating Fenfluramine Risk calculators and risk factors for Fenfluramine
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Fenfluramine | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Fenfluramine is a drug that was part of the Fen-Phen anti-obesity medication (the other drug being phentermine). Also known as Pondimin, fenfluramine was introduced on the U.S. market in 1973. It is the racemic mixture of two enantiomers, dexfenfluramine and levofenfluramine. It is designed to increase the level of the neurotransmitter serotonin, a chemical that regulates mood, appetite and other functions. Fenfluramine causes the release of serotonin by disrupting vesicular storage of the neurotransmitter, and reversing serotonin transporter function.[1] The end result is a feeling of fullness and loss of appetite.
The drug was withdrawn from the U.S. market in 1997 after reports of heart valve disease and pulmonary hypertension, including a condition known as cardiac fibrosis. After the US withdrawal of fenfluramine, it was also withdrawn from other markets around the world.
The distinctive valvular abnormality seen with fenfluramine is a thickening of the leaflet and chordae tendinae. Roth[2] suggested a mechanism by which fenfluramine damaged the valves. Heart valves also have serotonin receptors, which regulate their growth. He reported that fenfluramine and its active metabolite norfenfluramine stimulated the serotonin receptors 5-hydroxytryptamine (5-HT). In particular norfenfluramine is a potent agonist (stimulant) of 5-HT2B receptors. These receptors are plentiful in human cardiac valves and appear to be essential for normal cardiac development. Roth suggested that the mechanism by which fenfluramine causes damage is through inappropriately stimulating the valve cells to divide. This valve damage is found in other drugs that act on 5-HT2B receptors.
References
- ↑ Nestler, Eric J. "Molecular Neuropharmacology: A Foundation for Clinical Neuroscience" McGraw-Hill, 2001.
- ↑ Roth, B Drugs and Valvular Heart Disease. N Engl J Med 2007;356:6 PMID 17202450
External links
Phenethylamines |
|---|
| 2C-B • 2C-C • 2C-D • 2C-E • 2C-I • 2C-N • 2C-T-2 • 2C-T-21 • 2C-T-4 • 2C-T-7 • 2C-T-8 • 3C-E • 4-FMP • Bupropion • Cathine • Cathinone • Clenbuterol • DESOXY • Dextroamphetamine • Methamphetamine • Diethylcathinone • Dimethylcathinone • DOC • DOB • DOI • DOM • bk-MBDB • Dopamine • Br-DFLY • Ephedrine • Epinephrine • Escaline • Fenfluramine • Levalbuterol • Levmetamfetamine • MBDB • MDA • MDMA • MDMC • MDEA • MDPV • Mescaline • Methcathinone • Methylphenidate • Norepinephrine • Phentermine • Salbutamol • Tyramine • Venlafaxine |
Antiobesity preparations (A08) | |
|---|---|
| Centrally acting | Phentermine - Fenfluramine - Amfepramone - Dexfenfluramine - Mazindol - Cathine - Clobenzorex - Sibutramine - Rimonabant - Taranabant |
| Peripherally acting | Orlistat |
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
